Saxagliptin hydrate esceinamine Isomer II with a pharmacokinetic profile enabling

with a pharmacokinetic profile enabling long-acting drug efficacy

VPC-14337 (0-500 nM) inhibits proliferation of MCF-7 (luminal)

3-dihydropyridazine-4-carboxamide

BMS-345541 is also found to override the spindle checkpoint in nocodazole-arrested cells

Voronkov A

Saxagliptin hydrate esceinamine Isomer II with a pharmacokinetic profile enablingSaxagliptin, also known as BMS 477118, is a new oral hypoglycemic (anti diabetic drug) of the new dipeptidyl peptidase 4 (DPP 4) inhibitor class of drugs. Saxagliptin was approved in 2008 for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose